StrategyAzar Cheers Appeals Court Reversal on 340B Ruling
The ruling by the U.S. Court of Appeals for the District of Columbia reverses a lower court that said HHS...
StrategyMedicare Part D Premium Average Will Be $30.50 a Month in 2021
For the first time, Part D will cover insulin at a cost of no more than $35 a month per...
StrategyAvalere Health Analyzes Trump Drug Pricing Executive Orders
President Trump is scheduled to meet with pharmaceutical executives about the "most favored nation model" order on Tuesday.
StrategyPresident Trump Signs 4 Drug Pricing Executive Orders
President Trump added that the administration would have a "complete" healthcare plan to present "very shortly."
FinanceUnderstanding CMS' Proposed Value-based Purchasing Rule
An industry stakeholder says the proposal could be a "a positive sign" for providers entering value-based arrangements.
FinanceCMS Proposes Rule to Base Prescription Drug Payments on Patient Outcomes
CMS stated that the proposed rule will also bolster the agency's efforts to combat the opioid epidemic.
NursingManaging Medication Adherence During COVID-19
Coronavirus fears drive medication adherence ups and downs.
Clinical CareMedicare Part D Model Caps Insulin Copays at $35 a Month
Beneficiaries who use insulin and join a plan participating in the voluntary model, beginning January 2021, could see average out-of-pocket...
StrategyWhat We Know — and Don't Know — About Possible Coronavirus Treatments Promoted by Trump
There isn?t enough evidence that decades-old anti-malarial drugs work for the treatment or prevention of coronavirus, but here?s what we...
StrategyGilead Backtracks on Orphan Drug Designation for Remdesivir
NIH is testing the antiviral drug's safety and efficacy against COVID-19.
StrategyDoctors Are Hoarding Unproven Coronavirus Medicine by Writing Prescriptions for Themselves and Their Families
Demand for chloroquine and hydroxychloroquine surged over the past several days as President Donald Trump promoted them as possible treatments...
FinanceAllergan Reduces Operating Loss by 29%, Revenues Tick Up
The Dublin-based drugmaker improved on most financial metrics during 2019.